OTLC on OTC

Oncotelic Therapeutics, Inc.

American pharmaceutical preparations company based in Agoura Hills.

Price unavailable

Last updated Oct 18, 2026.

Overview

Compare with Silo Pharma, Inc., Inovio Pharmaceuticals or Benitec Biopharma Ltd, or pick any stock.

TickerOTLC on OTC
IndustryPharmaceutical Preparations
HeadquartersDE
Incorporated inDE²
Business address29397 Agoura Rd., #107, Aguora Hills, Ca 91301²
Filer categoryNon-accelerated filer, Smaller reporting company²

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2023

-9497.2%Operating margin³

-11290.1%Net margin³

-65.2%Return on equity³

Where the money goes

Where each dollar of revenue went, fiscal 2023

Interest

Research and development6¢$61.1K
Interest94¢$1.0M

Out of $70.0K in revenue.³⁴ The company lost money this year.

Financial statements

Revenue⁵³$70.0K in 2023−96% since 2020

Operating income⁶⁵⁷⁴³-$6.6M in 2023+54% since 2019

Net income⁶⁵⁷⁴³-$7.9M in 2023+19% since 2019

Every line of the income statement as filed: the last 2 fiscal years, latest first.¹⁰

Period ending	2025-12-31	2024-12-31
Research and development	$4.4K
General and administrative	$3.2M	$376.0K
Goodwill impairment (See note 2 and 3)		$3.2M
Total operating expenses	$3.2M	$3.6M
Income/(Loss) from operations	-$3.2M	-$3.6M
Change in fair value of investment in GMP Bio	$365.3M
Interest expense, net	-$885.5K	-$857.7K
Reimbursement for expenses - related party		$22.9K
Change in fair value of derivative on debt	$353.6K	-$280.4K
Loss on debt conversion	-$1.1M	-$88.3K
Miscellaneous income	$5.6K
Total other income (expense)	$363.8M	-$1.2M
Net income (loss) before income taxes	$360.6M	-$4.8M
Provision for income taxes	-$111.5M
Net income (loss) after income taxes before non-controlling interests	$249.0M	-$4.8M
Net loss attributable to non-controlling interests	-$254.9K	-$255.5K
Net income (loss) attributable to Oncotelic Therapeutics, Inc.	$249.3M	-$4.5M
Basic net income (loss) per share attributable to common stock	$0.59	$0.01
Basic weighted average common stock outstanding	421.0M shares	404.4M shares
Basic and diluted net income (loss) per share attributable to common stock	$0.59	-$0.01
Basic and diluted weighted average common stock outstanding	422.2M shares	404.4M shares

Total assets⁶⁵⁷⁴³$30.0M in 2023+27% since 2019

Total liabilities⁴³$18.4M in 2023+9% since 2022

Shareholders’ equity⁶⁵⁷⁴³$12.1M in 2023−28% since 2019

Cash⁶⁵⁷⁴$170.4K in 2023+108% since 2019

Every line of the balance sheet as filed: the last 3 fiscal years (annual) or 3 quarters (quarterly), latest first.¹⁰

Period ending	2025-12-31	2024-12-31	2023-12-31
Cash	$88.9K	$86.1K
Restricted cash	$20.0K	$20.0K
Accounts receivable	$51.3K	$19.0K
Prepaid & other current assets	$1.0M	$9.1K
Total current assets	$1.2M	$134.2K
In process R&D	$1.1M	$1.1M
Goodwill, net	$2.8M	$2.8M	$6.0M
Investment in GMP Bio at fair value	$388.0M	$22.7M
Total assets	$393.1M	$26.7M
Accounts payable and accrued liabilities	$2.6M	$2.4M
Contingent Consideration	$2.6M	$2.6M
Derivative liability on notes	$350.0K	$703.6K
Total current liabilities	$18.1M	$19.2M
Deferred income tax liability	$111.5M
Total liabilities	$131.4M	$19.2M
Convertible Preferred stock, $0.01 par value, 15,000,000 shares authorized; 24.388 and 0 shares issued and outstanding	$244
Common stock, $.01 par value; 750,000,000 shares authorized; 442,596,856 and 407,289,618 issued and outstanding, respectively	$4.4M	$4.1M
Additional paid-in capital	$47.1M	$42.2M
Accumulated equity (deficit)	$211.2M	-$38.0M
Total Oncotelic Therapeutics, Inc. stockholders equity	$262.8M	$8.3M
Non-controlling interests	-$1.0M	-$774.1K
Total stockholders equity	$261.7M	$7.5M	$11.6M
Total liabilities and stockholders equity	$393.1M	$26.7M
Preferred stock, par value	$0.01	$0.01
Preferred stock, shares authorized	15.0M shares	15.0M shares
Preferred stock, shares issued	24 shares	0 shares
Preferred stock, shares outstanding	24 shares	0 shares
Common stock, par value	$0.01	$0.01
Common stock, shares authorized	750.0M shares	750.0M shares
Common stock, shares issued	442.6M shares	407.3M shares
Common stock, shares outstanding	442.6M shares	407.3M shares

Period ending	2025-12-31	2024-12-31	2023-12-31
Cash	$88.9K	$86.1K
Restricted cash	$20.0K	$20.0K
Accounts receivable	$51.3K	$19.0K
Prepaid & other current assets	$1.0M	$9.1K
Total current assets	$1.2M	$134.2K
In process R&D	$1.1M	$1.1M
Goodwill, net	$2.8M	$2.8M	$6.0M
Investment in GMP Bio at fair value	$388.0M	$22.7M
Total assets	$393.1M	$26.7M
Accounts payable and accrued liabilities	$2.6M	$2.4M
Contingent Consideration	$2.6M	$2.6M
Derivative liability on notes	$350.0K	$703.6K
Total current liabilities	$18.1M	$19.2M
Deferred income tax liability	$111.5M
Total liabilities	$131.4M	$19.2M
Convertible Preferred stock, $0.01 par value, 15,000,000 shares authorized; 24.388 and 0 shares issued and outstanding	$244
Common stock, $.01 par value; 750,000,000 shares authorized; 442,596,856 and 407,289,618 issued and outstanding, respectively	$4.4M	$4.1M
Additional paid-in capital	$47.1M	$42.2M
Accumulated equity (deficit)	$211.2M	-$38.0M
Total Oncotelic Therapeutics, Inc. stockholders equity	$262.8M	$8.3M
Non-controlling interests	-$1.0M	-$774.1K
Total stockholders equity	$261.7M	$7.5M	$11.6M
Total liabilities and stockholders equity	$393.1M	$26.7M
Preferred stock, par value	$0.01	$0.01
Preferred stock, shares authorized	15.0M shares	15.0M shares
Preferred stock, shares issued	24 shares	0 shares
Preferred stock, shares outstanding	24 shares	0 shares
Common stock, par value	$0.01	$0.01
Common stock, shares authorized	750.0M shares	750.0M shares
Common stock, shares issued	442.6M shares	407.3M shares
Common stock, shares outstanding	442.6M shares	407.3M shares

Cash from operations⁶⁵⁷⁴³-$1.3M in 2023−42% since 2019

Every line of the cash flow as filed: the last 2 fiscal years, latest first.¹⁰

Period ending	2025-12-31	2024-12-31
Net income (loss)	$249.0M	-$4.8M
Goodwill impairment		$3.2M
Amortization of debt discount and deferred finance costs	$198.1K	$122.1K
Change in fair value of investment in GMP Bio	-$365.3M
Deferred income taxes	$111.5M
Stock compensation expense	$2.4M
Loss on debt conversion	$1.1M	$88.3K
Change in fair value of derivative	-$353.6K	$280.4K
Prepaid expenses and other current assets	$657	$53.2K
Accounts payable and accrued expenses	$103.7K	$293.2K
Accounts payable to related party	$2.1K	$2.0K
Net cash used in operating activities	-$1.4M	-$740.3K
Net proceeds from convertible debt	$478.0K
Proceeds from short term loans, others	$907.9K	$656.0K
Net cash provided by financing activities	$1.4M	$656.0K
Net increase (decrease) in cash	$2.7K	-$84.3K
Interest paid	$370.0K	$365.9K
Income taxes paid	$1.6K	$1.6K
Common shares issued upon partial conversion of debt	$479.6K	$645.4K

Compare Oncotelic Therapeutics, Inc. with another company

Leadership

Who has led Oncotelic Therapeutics, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

Chair

Vuong Trieu2019–now

President

Chief financial officer

Chief operating officer

Scott Young2006

2010201520202025

Chief executive officerVuong Trieu May 2, 2019 to now¹¹
Chief executive officerWilliam D. Schwieterman May 29, 2015 to Jun 22, 2018¹²
Chief executive officerDavid Chaplin May 19, 2014 to May 19, 2014¹³
Chief executive officerPeter Langecker Apr 29, 2010 to Aug 9, 2013¹⁴
Chief executive officerJohn A. Kollins Dec 18, 2008 to Jan 22, 2009¹⁵
Chief executive officerRichard Chin Jul 7, 2006 to Jan 15, 2008¹⁶
ChairVuong Trieu May 2, 2019 to now¹¹
PresidentWilliam D. Schwieterman May 29, 2015 to Jun 22, 2018¹²
PresidentDavid Chaplin May 19, 2014 to May 19, 2014¹³
PresidentRichard Chin Jul 7, 2006 to Jan 15, 2008¹⁶
Chief financial officerMatthew M. Loar Jul 20, 2015 to Jun 22, 2018¹⁷
Chief financial officerBarbara Riching Feb 28, 2013 to May 29, 2015¹⁸
Chief financial officerDavid Louis Johnson Apr 3, 2012 to Apr 3, 2012¹⁹
Chief financial officerJames B. Murphy Jun 16, 2006 to Sep 17, 2010²⁰
Chief operating officerScott Young Jun 16, 2006 to Jun 16, 2006²¹

Board members and other officers (33)

CRO/CMOSeymour Howard Fein Jul 23, 2026 to now²²
CHIEF CLINICAL OFFICERAnthony E. Maida Iii. Jul 16, 2021 to now²³
CHIEF BUSINESS OFFICERSaran Saund Jul 16, 2021 to now²⁴
Chief Technical OfficerChulho Park May 2, 2019 to Nov 23, 2020²⁵
Chief Medical OfficerFatih Uckun May 2, 2019 to May 2, 2019²⁶
ControllerPamela Ha Jun 12, 2015 to Jun 12, 2015²⁷
Dir. of Finance, Interim PFOBarbara Riching Jul 31, 2012 to Jul 31, 2012²⁸
Chief Development OfficerPeter Langecker Jun 30, 2009 to Jun 30, 2009²⁹
Chief Scientific OfficerDavid Chaplin Feb 6, 2007 to Jan 13, 2017³⁰
Sr. VP, Chief Business OfficerJohn A. Kollins Mar 5, 2007 to May 1, 2007³¹
VP and Chief Medical OfficerPatricia A. Walicke Aug 6, 2007 to Jan 22, 2009³²
Board memberVuong Trieu Sep 8, 2021 to Sep 8, 2021³³
Board memberAnthony E. Maida Iii. May 21, 2020 to now³⁴
Board memberSimon Pedder Mar 23, 2016 to Jun 22, 2018³⁵
Board memberBobby W. Sandage Phd. Oct 27, 2016 to Jun 22, 2018³⁶
Board memberDonald Rogers Reynolds Oct 27, 2016 to Jun 22, 2018³⁷
Board memberFrederick W. Driscoll Jan 6, 2014 to Jun 3, 2016³⁸
Board memberGerald McMahon Phd. Sep 12, 2011 to Jun 3, 2016³⁹
Board memberTamar D. Howson Apr 6, 2010 to May 29, 2015⁴⁰
Board memberPeter Langecker Apr 29, 2010 to Aug 9, 2013¹⁴
Board memberHarri Taranto V. Aug 12, 2009 to Aug 12, 2009⁴¹
Board memberAlastair Jj Wood Oct 31, 2008 to Jul 2, 2013⁴²
Board memberMark Kessel Oct 31, 2008 to Apr 12, 2012⁴³
Board memberJohn A. Kollins Dec 18, 2008 to Jan 22, 2009¹⁵
Board memberDavid Chaplin Feb 6, 2007 to Jun 22, 2018³⁰
Board memberRoy H. Fickling Jun 28, 2007 to Jan 4, 2011⁴⁴
Board memberWilliam D. Schwieterman Jun 28, 2007 to Jun 22, 2018⁴⁵
Board memberArthur B. Laffer Mar 6, 2006 to Jan 5, 2010⁴⁶
Board memberJoel Tomas Citron Mar 8, 2006 to Nov 22, 2006⁴⁷
Board memberPer Olof Soderberg Mar 17, 2006 to Dec 18, 2006⁴⁸
Board memberRichard Zecher Apr 4, 2006 to Apr 4, 2006⁴⁹
Board memberRichard Chin Jul 7, 2006 to Jan 15, 2008¹⁶
Board memberWilliam N. Shiebler Aug 2, 2006 to Nov 2, 2011⁵⁰

Former names

MATEON THERAPEUTICS INCJun 17, 2016 to Mar 26, 2021²
OXIGENE INCOct 24, 1996 to Jun 3, 2016²

Timeline

May 2, 2019New chief executive Vuong Trieu becomes CEO¹¹
May 29, 2015New chief executive William D. Schwieterman becomes CEO¹²
May 19, 2014New chief executive David Chaplin becomes CEO¹³
Apr 29, 2010New chief executive Peter Langecker becomes CEO¹⁴
Dec 18, 2008New chief executive John A. Kollins becomes CEO¹⁵
Jul 7, 2006New chief executive Richard Chin becomes CEO¹⁶

Filings

136 filings to the SEC since October 2021: 6 annual reports, 15 quarterly reports, 55 major events, 25 insider forms, 3 private raises, 32 other. The latest 20:

Oct 13, 20268-K EDGAR
Aug 13, 202610-Q EDGAR
Aug 4, 20268-K EDGAR
Jul 23, 20264 EDGAR
Jul 22, 2026D EDGAR
Jul 21, 20264 EDGAR
Jul 14, 20268-K EDGAR
Jul 14, 20268-K EDGAR
Jul 14, 20264 EDGAR
Jul 14, 20264 EDGAR
Jul 14, 20264 EDGAR
Jul 14, 20264 EDGAR
Jul 2, 20264 EDGAR
Jun 29, 20268-K EDGAR
Jun 24, 20264 EDGAR
Jun 22, 20264 EDGAR
Jun 17, 20264 EDGAR
May 14, 202610-Q EDGAR
May 5, 20268-K EDGAR
Apr 16, 20268-K EDGAR

The 136 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last three years, summarized. The full record is on SEC EDGAR.

Money raised

Private offerings the company reported to the SEC on Form D.

Jul 10, 2026Raised $711,840 in a private offering of equity Form D: 33 investors so far Form D
Dec 4, 2025Raised $275,000 in a private offering of securities Form D: $12.5 million offered in all Form D
Jul 13, 2023Filed a private offering of debt Form D: $5 million offered in all Form D

Sources

The numbers on this page point here. Each one links to the record it came from.

1
SEC EDGAROncotelic Therapeutics, Inc. filings on SEC EDGAR
2
SEC EDGAROncotelic Therapeutics, Inc. filings on SEC EDGAR
3
SEC EDGAROncotelic Therapeutics, Inc. 10-K for fiscal 2023
4
SEC EDGAROncotelic Therapeutics, Inc. 10-K for fiscal 2023
5
SEC EDGAROncotelic Therapeutics, Inc. 10-K for fiscal 2020
6
SEC EDGAROncotelic Therapeutics, Inc. 10-K for fiscal 2019
7
SEC EDGAROncotelic Therapeutics, Inc. 10-K for fiscal 2021
8
SEC EDGAROncotelic Therapeutics, Inc. 10-Q for fiscal 2026
9
SEC EDGAROncotelic Therapeutics, Inc. 10-Q for fiscal 2026
10
SEC EDGAROncotelic Therapeutics, Inc. 10-K filed 2026-04-15: income statement
11
SEC EDGARVuong Trieu, Chief executive officer
12
SEC EDGARWilliam D. Schwieterman, Chief executive officer
13
SEC EDGARDavid Chaplin, Chief executive officer
14
SEC EDGARPeter Langecker, Chief executive officer
15
SEC EDGARJohn A. Kollins, Chief executive officer
16
SEC EDGARRichard Chin, Chief executive officer
17
SEC EDGARMatthew M. Loar, Chief financial officer
18
SEC EDGARBarbara Riching, Chief financial officer
19
SEC EDGARDavid Louis Johnson, Chief financial officer
20
SEC EDGARJames B. Murphy, Chief financial officer
21
SEC EDGARScott Young, Chief operating officer
22
SEC EDGARSeymour Howard Fein, CRO/CMO
23
SEC EDGARAnthony E. Maida Iii., CHIEF CLINICAL OFFICER
24
SEC EDGARSaran Saund, CHIEF BUSINESS OFFICER
25
SEC EDGARChulho Park, Chief Technical Officer
26
SEC EDGARFatih Uckun, Chief Medical Officer
27
SEC EDGARPamela Ha, Controller
28
SEC EDGARBarbara Riching, Dir. of Finance, Interim PFO
29
SEC EDGARPeter Langecker, Chief Development Officer
30
SEC EDGARDavid Chaplin, Chief Scientific Officer
31
SEC EDGARJohn A. Kollins, Sr. VP, Chief Business Officer
32
SEC EDGARPatricia A. Walicke, VP and Chief Medical Officer
33
SEC EDGARVuong Trieu, Board member
34
SEC EDGARAnthony E. Maida Iii., Board member
35
SEC EDGARSimon Pedder, Board member
36
SEC EDGARBobby W. Sandage Phd., Board member
37
SEC EDGARDonald Rogers Reynolds, Board member
38
SEC EDGARFrederick W. Driscoll, Board member
39
SEC EDGARGerald McMahon Phd., Board member
40
SEC EDGARTamar D. Howson, Board member
41
SEC EDGARHarri Taranto V., Board member
42
SEC EDGARAlastair Jj Wood, Board member
43
SEC EDGARMark Kessel, Board member
44
SEC EDGARRoy H. Fickling, Board member
45
SEC EDGARWilliam D. Schwieterman, Board member
46
SEC EDGARArthur B. Laffer, Board member
47
SEC EDGARJoel Tomas Citron, Board member
48
SEC EDGARPer Olof Soderberg, Board member
49
SEC EDGARRichard Zecher, Board member
50
SEC EDGARWilliam N. Shiebler, Board member